NCT03615066View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

December 12, 2019

Study Completion Date

April 12, 2021

Conditions
Chronic Hepatitis B
Interventions
DRUG

Placebo

Tablet(s) administered orally every 7 days for 24 doses in fasted state

DRUG

Selgantolimod

Tablet(s) administered orally every 7 days for 24 doses in fasted state

DRUG

TAF

Tablet(s) administered orally once daily with food

Trial Locations (10)

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

10002

National Taiwan University Hospital, Taipei

82445

E-Da Hospital, Kaohsiung City

T2N4Z6

University of Calgary Liver Unit - Heritage Medical Research Clinic, Calgary

M5G 2C4

University Health Network, Toronto General Hospital, Toronto Centre for Liver Disease, Toronto

M6H 3M1

Toronto Liver Centre, Toronto

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

06973

Chung-Ang University Hospital, Seoul

120-752

Severance Hospital, Yonsei University Health System, Seoul

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT03615066 - Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment | Biotech Hunter | Biotech Hunter